title: Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
abstract: Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.
authors.affiliation: Departments of Pathology and Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
authors.forename: Katerina
authors.initials: K
authors.lastname: Politi
authors.affiliation: Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
authors.forename: Scott
authors.initials: S
authors.lastname: Gettinger
mesh_terms: D002227:Carbazoles / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D009154:Mutation; D010880:Piperidines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics*
chemical_list: D002227:Carbazoles; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases